Open AccessAndrogen receptor signalling confers clonogenic and migratory advantages in urothelial cell carcinoma of the bladder
Author(s) -
LunaVelez Maria V.,
Dijkstra Jelmer J.,
Heuschkel Marina A.,
Smit Frank P.,
van de Zande Guillaume,
Smeets Dominique,
Sedelaar J. P. Michiel,
Vermeulen Michiel,
Verhaegh Gerald W.,
Schalken Jack A.
Publication year - 2021
Publication title -
molecular oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.332
H-Index - 88
eISSN - 1878-0261
pISSN - 1574-7891
DOI - 10.1002/1878-0261.12957
Subject(s) - androgen receptor , clonogenic assay , cancer research , gene knockdown , androgen , enzalutamide , biology , downregulation and upregulation , cell , medicine , cancer , endocrinology , cell culture , prostate cancer , hormone , gene , biochemistry , genetics
Bladder urothelial cell carcinoma (UCC) incidence is about three times higher in men compared with women. There are several indications for the involvement of hormonal factors in the aetiology of UCC. Here, we provide evidence of androgen signalling in UCC progression. Microarray and qPCR analysis revealed that the androgen receptor ( AR ) mRNA level is upregulated in a subset of UCC cases. In an AR‐positive UCC‐derived cell line model, UM‐UC‐3‐AR, androgen treatment increased clonogenic capacity inducing the formation of big stem cell‐like holoclones, while AR knockdown or treatment with the AR antagonist enzalutamide abrogated this clonogenic advantage. Additionally, blockage of AR signalling reduced the cell migration potential of androgen‐stimulated UM‐UC‐3‐AR cells. These phenotypic changes were accompanied by a rewiring of the transcriptome with almost 300 genes being differentially regulated by androgens, some of which correlated with AR expression in UCC patients in two independent data sets. Our results demonstrate that AR signals in UCC favouring the development of an aggressive phenotype and highlights its potential as a therapeutic target for bladder cancer.